However, Gebauer et al. [9] found that EBV+ DLBCL exhibited few mutations affecting CD79B and CARD11, and no mutations in MYD88. This suggested that EBV-mediated activation of NF-kB may occur as an alternative to pathologically enforced B-cell receptor signaling in this rare lymphoma. This evidence concerns the gene CD79B and lymphoma.